Cat:GMP-h-p-tau217
Awaiting product image
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-h-p-tau217 Categories , Tag

For more than 100mg, click here for inquiry. >>

Product Details

Genemedi produces core diagnostic ingredients for test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome. GeneMedi offers paired diagnostics grade Phospho-tau217 (p-tau217) antibodies (monoclonal antibody, mab) and antigens for Neurodegenerative diseases (Alzheimer Disease(AD)) rapid test kit of Phospho-tau217 (p-tau217) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Neurodegenerative diseases (Alzheimer Disease(AD) ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Alzheimer Disease(AD) ?Recent publications and meeting presentations bolster the evidence that upticks in p-tau181, p-tau217, and p-tau231 occur soon after Aβ begins to accumulate in the brain. That’s years before neurofibrillary tangles can be detected by PET, and decades before symptoms. Researchers predict these markers, which also distinguish AD from other forms of dementia, will lead to more robust tests than those based on Aβ, because of their larger dynamic range—phosphorylated fragments of tau climb by as much as 10-fold in the blood as AD progresses, whereas the Aβ42/40 ratio falls by about 15 percent at most.

Product Description

Cat No. of Pruducts

GMP-h-p-tau217-Ag01:Recombinant Human p-tau217 Protein

Product Name

Recombinant Human p-tau217 Protein

Target

Phospho-tau217

Alias of Target/Biomarker

DDPAC, FTDP-17L, MSTD, MTBT1, MTBT2, PPND, PPP1R103,?TAU,?tau-40, MAPT

Expression platform

synthesized

Isotypes

NA

Bioactivity validation

Phospho-tau217 (p-tau217) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in p-tau217 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation

Tag

Products description

Recombinant Human p-tau217 Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.

Reconized/Reactive Species

Human

Purity

Purity: ≥95%?（SDS-PAGE）

Application

positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Genemeidi Omicron Variant Products
test
Previous slide
Next slide

Cat No. of Pruducts

GMP-h-p-tau217-Ab01,GMP-h-p-tau217-Ab02:Anti-Human p-tau217 mouse monoclonal antibody (mAb)

Product Name

Anti-Human p-tau217 mouse monoclonal antibody (mAb)

Target

Phospho-tau217 (p-tau217)

Alias of Target/Biomarker

DDPAC, FTDP-17L, MSTD, MTBT1, MTBT2, PPND, PPP1R103,?TAU,?tau-40, MAPT

Expression platform

Hybridoma

Isotypes

Mouse IgG

Bioactivity validation

Human Phospho-tau217 (p-tau217) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Phospho-tau217 (p-tau217) antibodies in p-tau217 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation.

Tag

mFc

Products description

Anti-Human p-tau217 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Phospho-tau217 (p-tau217) antibodies.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1

Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.